GlassScriptPhysician profile
Nabeel A Khan
NPI 1144218066
$2,294.44
in general payments reported to CMS, 2019-2025
21 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $75.58 · 2021: $1,323 · 2022: $181 · 2023: $91.92 · 2024: $82.99 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $290.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prodigy Surgical Distribution, INC. | $1,200.00 | 2021 | |
| Novo Nordisk INC | $294.28 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $238.77 | 2019-2023 | |
| Lilly USA, LLC | $88.42 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $80.40 | 2019-2024 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $50.19 | 2019-2021 | |
| Amgen INC. | $42.98 | 2020-2025 | Repatha, Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $36.11 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $31.41 | 2019 | |
| Exact Sciences Corporation | $30.44 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $26.98 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.98 | 2019-2021 | |
| Abbvie INC. | $22.18 | 2025 | |
| Merck Sharp & Dohme LLC | $21.61 | 2022 | |
| Abbott Laboratories | $16.26 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $15.97 | 2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $15.63 | 2019 | |
| Glaxosmithkline, LLC. | $14.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.61 | 2019 | |
| Esperion Therapeutics, INC. | $14.14 | 2024 | Nexletol |
| Amarin Pharma, INC. | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabeel Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.